An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children

被引：7

作者：

Lauvau, DVA ^{[1
]}

Verbist, L ^{[1
]}

Abrassart, C ^{[1
]}

Adriaens, F ^{[1
]}

Andre, F ^{[1
]}

Bockaert, K ^{[1
]}

Bodart, E ^{[1
]}

Bricteux, G ^{[1
]}

Casneuf, J ^{[1
]}

Cassiers, M ^{[1
]}

Chefneux, A ^{[1
]}

DeNayer, J ^{[1
]}

Dechamps, L ^{[1
]}

Deurinck, M ^{[1
]}

Devriendt, E ^{[1
]}

Dockx, M ^{[1
]}

Ehrentreich, U ^{[1
]}

Fafchamps, Y ^{[1
]}

Geuens, M ^{[1
]}

Hecquet, T ^{[1
]}

Hendrickx, G ^{[1
]}

Israel, E ^{[1
]}

Jadoul, R ^{[1
]}

Krygier, A ^{[1
]}

Lagasse, E ^{[1
]}

Lamotte, PJ ^{[1
]}

Legrand, B ^{[1
]}

Lemahieu, R ^{[1
]}

Malchair, R ^{[1
]}

Maquet, JC ^{[1
]}

Mertens, G ^{[1
]}

Neufcoeur, JP ^{[1
]}

Pieraert, C ^{[1
]}

Pierquin, G ^{[1
]}

Prudhomme, J ^{[1
]}

Reginster, L ^{[1
]}

Ureel, D ^{[1
]}

VanBiervliet, JP ^{[1
]}

VanDenNoortgaete, M ^{[1
]}

VanMelkebeke, E ^{[1
]}

Vandenbossche, L ^{[1
]}

Verboven, M ^{[1
]}

Vertruyen, A ^{[1
]}

Zasinska, E ^{[1
]}

Zeligzon, A ^{[1
]}

机构：

[1] ALGEMEEN ZIEKENHUIS ST VINCENTIUS, GHENT, BELGIUM

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 1997年 / 25卷 / 05期

关键词：

azithromycin; co-aimoxiclav; antibacterial; streptococcal pharyngitis; tonsillitis; bronchitis; pneumonia; children;

D O I：

10.1177/030006059702500506

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

An open prospective, multicentre, comparative, randomized (2:1) study was conducted in 481 children diagnosed as having mild-to-moderate lower respiratory tract infections. The efficacy and safety of azithromycin suspension (10 mg/kg), dosed orally once daily for 3 days, was compared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally three times daily for 5 - 10 days. The proportion of evaluable patients (n = 472) showing a cure or improvement was significantly higher in the azithromycin group (96.8%) than in the co-amoxiclav group (91%, P = 0.0199). There were six relapses in both groups, giving an overall response rate of 95% for azithromycin versus 87.1% for co-amoxiclav (P = 0.0025). Adverse events were reported in 10% of the patients treated with azithromycin, and 11.3% of co-amoxiclav patients. Reported and counted compliance was significantly better in the azithromycin group. A 3-day regimen of azithromycin was as effective and as safe as a 5 - 10 day regimen of co-amoxiclav in the treatment of respiratory tract infections in children, and compliance was improved.

引用

页码：285 / 295

页数：11

共 14 条

[1]

BALDWIN DR, 1990, EUR RESPIR J, V3, P886

[2] EFFECTS OF INTERVENTION ON ANTIBIOTIC COMPLIANCE IN PATIENTS IN GENERAL-PRACTICE [J].